Glycotest Diagnostics

Executive Summary

Glycotest Diagnostics is a privately-held, US-based diagnostics company focused on developing non-invasive, blood-based tests for the early detection and surveillance of liver cancers and fibrosis-cirrhosis. Leveraging proprietary glycomic biomarker technology, the company aims to address the significant unmet need for accurate, accessible screening tools in chronic liver disease, which affects millions worldwide. Currently, diagnosis often relies on invasive biopsies or less sensitive imaging, leading to late-stage detection. Glycotest's platform promises to enable earlier intervention, potentially improving patient outcomes and reducing healthcare costs. The company was founded in 2015 and is headquartered in Baltimore, Maryland, but remains in a developmental stage with no commercial products yet approved. While Glycotest's technology is compelling and addresses a critical gap in liver disease management, the company faces typical early-stage risks, including the need for clinical validation, regulatory clearance, and commercial scaling. No significant funding rounds, partnerships, or clinical trial milestones have been publicly disclosed, making it difficult to assess near-term progress. The convergence of advanced glycomics and the growing demand for non-invasive diagnostics positions Glycotest as a potential disruptor, but execution and capital remain key uncertainties. Its success will hinge on validating test performance in large-scale studies and securing strategic partnerships for manufacturing and distribution.

Upcoming Catalysts (preview)

• Q1 2027Initiation of a pivotal clinical trial for liver cancer detection test60% success
• Q4 2026Publication of new clinical validation data in a peer-reviewed journal70% success
• Q2 2027Series A or B funding round to support product development50% success